TrialCompass™ TCL
Back to results
Phase 3RecruitingPriority 2 · High priorityNCT06522737

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

ClinicalTrials.gov

Plain-language summary

This Phase 3 trial is comparing Duvelisib, Gemcitabine, and other medications against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Duvelisib (DRUG): oral capsules | Gemcitabine (DRUG): solution for intravenous infusion | Bendamustine (DRUG): solution for intravenous infusion

Drugs / treatments
Duvelisib, Gemcitabine, Bendamustine
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737

Phase: Phase 3 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 3 trial is comparing Duvelisib, Gemcitabine, and other medications against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

What's being tested

Duvelisib (DRUG): oral capsules | Gemcitabine (DRUG): solution for intravenous infusion | Bendamustine (DRUG): solution for intravenous infusion

Drugs / treatments: Duvelisib, Gemcitabine, Bendamustine

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, open-label

Enrollment target: 124 patients

Primary endpoint: Progression-free Survival (PFS) as assessed by the Independent Review Committee (IRC)

Ages: 18 Years to —

Start date: 2025-05-19 | Est. completion: 2028-12

Locations

0 US sites · 44 total

Contact

Ohad Bentur | TerzoMM@securabio.com | (702) 254-0011

Sponsor: SecuraBio (INDUSTRY)

Tags

AITL/TFH · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06522737

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.